Success is hard to come by in drug development. “On average, 50% of phase III trials with novel therapeutics fail,” says Subha Madhavan, vice president and head of AI/ML at Pfizer. “A primary reason ...
The sharing of patient-level data necessary for covariate-adjusted survival analysis between medical institutions is difficult due to privacy protection restrictions. We propose a privacy-preserving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results